Yuzana Zaw, MD
Nephrology · Phoenix, AZNPI 1013313451
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,926 of the $3,428 with a category attached, or 85.4%. It is spread thinly across 24 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,421, 5.8 times the $247 reported in 2019.
Across 170 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$651
- Mallinckrodt Hospital Products Inc.$522
- Amgen$402
- AstraZeneca$312
- OPKO Pharmaceuticals, LLC$254
- Daiichi Sankyo Inc.$216
- plus $1K from 18 others
Across 37 payments — averaging $4245.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$144K
- Gilead$13K
What the payments were for
- Food & beverage$2,92685%
- Education$50115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $651 |
| Mallinckrodt Hospital Products Inc. | 17 | $522 |
| Amgen(2 entities) | 21 | $402 |
| AstraZeneca(2 entities) | 17 | $312 |
| OPKO Pharmaceuticals, LLC | 14 | $254 |
| Daiichi Sankyo Inc. | 10 | $216 |
| Bayer | 12 | $211 |
| Novartis | 7 | $128 |
| Ardelyx, Inc. | 5 | $86 |
| Calliditas Therapeutics US Inc. | 3 | $79 |
| Travere Therapeutics, Inc. | 7 | $74 |
| Aurinia Pharma U.S., Inc. | 3 | $71 |
| Vifor Pharma, Inc. | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| Boehringer Ingelheim | 2 | $49 |
| Novo Nordisk | 2 | $48 |
| Fresenius USA Marketing, Inc. | 2 | $39 |
| Outset Medical Inc | 1 | $33 |
| Chiesi USA, Inc. | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $28 |
| Renalytix AI, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Akebia Therapeutics Inc | 2 | $19 |
| GSK | 1 | $13 |
How this compares
$3,428 in reported general payments places this provider in the 60th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TarpeyoBudesonide | 12 | $186,545 |
| VelphoroSucroferric Oxyhydroxide | 29 | $96,741 |
| FarxigaDapagliflozin Propanediol | 61 | $75,010 |
| RayaldeeCalcifediol | 17 | $20,965 |
| KerendiaFinerenone | 17 | $14,655 |
| LokelmaSodium Zirconium Cyclosilicate | 32 | $13,190 |
| Sevelamer Carbonate | 41 | $4,253 |
| Calcitriol | 56 | $1,333 |
| Midodrine Hcl | 17 | $1,316 |
| Losartan Potassium | 61 | $571 |
| Allopurinol | 44 | $491 |
| Hydralazine Hcl | 25 | $352 |
| Torsemide | 17 | $261 |
| Carvedilol | 32 | $238 |
| Lisinopril | 29 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Calliditas Therapeutics US Inc.Tarpeyo | $79 | $186,54512 claims |
| Fresenius USA Marketing, Inc.Velphoro | $39 | $96,74129 claims |
| AstraZenecaFarxiga, Lokelma | $312 | $88,19993 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $254 | $20,96517 claims |
| BayerKerendia | $211 | $14,65517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 259 nephrology providers in Arizona.
Other nephrology in Phoenix
- Samer Bani HaniPhoenix$54K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Edgardo LaurelPhoenix$15K
- Sharareh SaadatPhoenix$15K
- Amar BistaPhoenix$12K
- Maher MousaPhoenix$9K
- Paul SacksPhoenix$8K
- William WeissPhoenix$8K
- Esmat MustafaPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.